Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology:

In this short interview from HF 22, Prof Lars Lund (Karolinska Institute, Stockholm, SE) joins us on-site to discuss the outcomes of the Ghrelin-HF study. This was a placebo controlled, randomised trial that evaluated the effects of intravenous ghrelin in patients with heart failure with preserved ejection fraction (HFpEF).

Discussion Points:

-Aims of This Study
-Mechanism of Action
-Patient Cohort and Study Design
-Key Findings
-Take-Home Messages

Recorded on-site at HF, Madrid, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "Heart Failure 2022: Ghrelin-HF: Intravenous Ghrelin In Patients with HFpEF | Prof Lars Lund" передвинте ползунок вправо